Long-term follow-up data from the phase III KATHERINE study in people with HER2-positive early-stage breast cancer who have residual invasive disease following neoadjuvant treatment showed that a statistically significant and clinically meaningful improvement in overall survival, a secondary endpoint, was observed with adjuvant Kadcyla (ado-trastuzumab emtansine) compared to Herceptin (trastuzumab).
Hope S. Rugo has joined City of Hope to lead its Women’s Cancers Program throughout the organization and breast medical oncology division section.
